April 1, 1998Diabetes
Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene.
Why the study?
Does genetic variability in the SUR1 gene associate with NIDDM and alter pancreatic beta-cell function in response to tolbutamide?
Population
NIDDM patients (up to n=406) and unrelated, healthy, young Danish Caucasians (up to n=380)
Comparison
Intravenous glucose and tolbutamide loads vs Subjects without the at-risk SUR1 combined…
Design
Case-control
Authors
Discussion
Loading...
Member takes
Overview
These SUR1 variants warrant replication; should not yet alter sulfonylurea selection in NIDDM.
Structured PICO
Does genetic variability in the SUR1 gene associate with NIDDM and alter pancreatic beta-cell function in response to tolbutamide?
P
Population
NIDDM patients (up to n=406) and unrelated, healthy, young Danish Caucasians (up to n=380)
I
Intervention
Intravenous glucose and tolbutamide loads (in healthy subjects)
C
Comparator
Subjects without the at-risk SUR1 combined genotype
O
Outcome
Association of SUR1 gene variants with NIDDM and influence on insulin and C-peptide secretion after intravenous glucose and tolbutamide loadssurrogate
A silent polymorphism in exon 18 of the SUR1 gene, combined with an intron variant, is associated with NIDDM and reduced beta-cell response to tolbutamide in healthy carriers.
Cite This Study
Hansen et al. (1998) studied this question.